BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences:
TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHA
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 1:00 p.m. ET
Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET
Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, June 10, 2025
Time: 4:00 p.m. ET
The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 90 days following the conclusion of the live event.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.
Last Trade: | US$19.02 |
Daily Change: | 0.59 3.20 |
Daily Volume: | 551,043 |
Market Cap: | US$1.130B |
August 25, 2025 August 13, 2025 June 13, 2025 June 13, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load